Amgen (AMGN) Tops Q3 EPS by 23c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Leerink Partners Cuts Price Target on Amgen (AMGN); Reiterates Market Perform
October 28, 2016 7:05 AM EDTLeerink Partners maintained a Market Perform rating on Amgen (NASDAQ: AMGN), and cut the price target to $163.00 (from $193.00), following the company's 2Q earnings report. Total product revenues of $5.516bn were in line with consensus and 4% under forecasts. Epogen declined less than expected and beat consensus by 10%. On the conference call management stated that given the contract terms they have committed to, in order to protect Enbrels formulary position, they are anticipating that in 2017 Enbel will not benefit at all from net price increases.
Analyst Geoffrey Porges commented, "Amgen Reported Q2... More
